Arbutus Narrows Losses by 48% on Soaring Revenue, Cost Cuts

TL;DR

ABUS is burning less cash and making more money from licenses, but the real upside is in those massive LNP patent lawsuits against Moderna and Pfizer.

AI Summary

Arbutus Biopharma Corp (ABUS) reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $29.7 million from $57.4 million in the prior year, a 48.2% improvement. Total revenue saw a substantial increase to $13.0 million for the nine months ended September 30, 2025, up from $4.6 million in the same period of 2024, primarily driven by collaborations and licenses revenue which surged to $11.8 million from $2.9 million. Operating expenses were significantly curtailed, falling to $45.9 million from $67.0 million year-over-year, a 31.5% reduction, largely due to decreased research and development expenses, which dropped to $20.2 million from $45.2 million. The company's cash, cash equivalents, and marketable securities totaled $93.7 million as of September 30, 2025, down from $122.6 million at December 31, 2024. Arbutus is actively pursuing intellectual property lawsuits against Moderna and Pfizer/BioNTech regarding LNP technology, with a trial against Moderna set for March 2026 and a favorable claim construction ruling in the Pfizer/BioNTech case in September 2025. The company believes it has sufficient cash resources to fund operations for at least the next 12 months.

Why It Matters

This 10-Q reveals Arbutus Biopharma is making strides in financial efficiency, significantly cutting its net loss and operating expenses while boosting collaboration revenue. For investors, this signals a more sustainable burn rate and potential for future profitability, especially if their ongoing LNP patent lawsuits against Moderna and Pfizer/BioNTech yield substantial settlements or royalties. Employees might see increased job security as the company's financial health improves. Customers, particularly those awaiting treatments for chronic hepatitis B, could benefit from continued R&D into drugs like imdusiran and AB-101. In the competitive biopharma landscape, successful patent defense could solidify Arbutus's position as a key innovator in LNP technology, impacting the broader mRNA vaccine market.

Risk Assessment

Risk Level: medium — While Arbutus has reduced its net loss and operating expenses, the company remains in a net loss position of $29.7 million for the nine months ended September 30, 2025. Its cash and investments decreased by $28.9 million from December 31, 2024, to $93.7 million, indicating continued cash burn. The company's future largely hinges on the outcome of complex, high-stakes intellectual property litigation against Moderna and Pfizer/BioNTech, which introduces significant legal and financial uncertainty.

Analyst Insight

Investors should monitor the progress of Arbutus's LNP patent lawsuits against Moderna and Pfizer/BioNTech closely, as these legal outcomes represent a significant potential catalyst or risk. Given the reduced cash burn and increased collaboration revenue, existing shareholders might consider holding, while new investors could look for entry points after further clarity on the litigation, as a favorable ruling could dramatically re-rate the stock.

Financial Highlights

debt To Equity

0.26

revenue

$13.0M

operating Margin

-252.5%

total Assets

$97.7M

total Debt

$20.3M

net Income

-$29.7M

eps

-$0.16

gross Margin

N/A

cash Position

$93.7M

revenue Growth

+183.5%

Revenue Breakdown

Key Numbers

• $29.7M — Net Loss (Reduced from $57.4M in 2024, a 48.2% improvement for nine months ended Sep 30, 2025)
• $13.0M — Total Revenue (Increased from $4.6M in 2024 for nine months ended Sep 30, 2025)
• $11.8M — Collaborations and Licenses Revenue (Increased from $2.9M in 2024 for nine months ended Sep 30, 2025)
• $45.9M — Total Operating Expenses (Reduced from $67.0M in 2024, a 31.5% decrease for nine months ended Sep 30, 2025)
• $20.2M — Research and Development Expenses (Reduced from $45.2M in 2024 for nine months ended Sep 30, 2025)
• $93.7M — Cash, Cash Equivalents, and Marketable Securities (As of September 30, 2025, down from $122.6M at December 31, 2024)
• 192,324,017 — Common Shares Outstanding (As of November 11, 2025)
• $0.04 — Net Loss Per Common Share (Basic and Diluted) (For the three months ended September 30, 2025, down from $0.10 in 2024)

Key Players & Entities

• Moderna Therapeutics, Inc. (company) — defendant in LNP patent lawsuit
• Pfizer Inc. (company) — defendant in LNP patent lawsuit
• BioNTech SE (company) — defendant in LNP patent lawsuit
• Genevant Sciences GmbH (company) — co-plaintiff in international lawsuits against Moderna
• imdusiran (AB-729) (product) — proprietary RNAi therapeutic in development
• AB-101 (product) — proprietary oral PD-L1 inhibitor in development
• The Nasdaq Stock Market LLC (regulator) — exchange where common shares are registered
• United States Securities and Exchange Commission (regulator) — filing oversight

FAQ

Risk Factors

• Intellectual Property Litigation [high — legal]: Arbutus is actively engaged in significant intellectual property lawsuits against Moderna and Pfizer/BioNTech concerning LNP technology. A trial against Moderna is scheduled for March 2026, and a favorable claim construction ruling was obtained in the Pfizer/BioNTech case in September 2025. The outcomes of these litigations could materially impact the company's financial condition and future prospects.
• Cash Burn and Funding Needs [medium — financial]: The company's cash, cash equivalents, and marketable securities decreased to $93.7 million as of September 30, 2025, from $122.6 million at December 31, 2024. While management believes current resources are sufficient for at least the next 12 months, ongoing litigation and R&D activities represent substantial cash outflows.
• Research and Development Expenses [medium — operational]: R&D expenses were significantly reduced to $20.2 million for the nine months ended September 30, 2025, down from $45.2 million in the prior year. While this contributed to improved net loss, further investment may be required to advance pipeline candidates.
• Drug Development and Approval [high — regulatory]: As a biopharmaceutical company, Arbutus faces inherent risks associated with the lengthy and costly process of drug development, clinical trials, and regulatory approvals. Failure to achieve regulatory milestones for its drug candidates could significantly impact its business.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on intellectual property protection and strategic partnerships or litigation to monetize their innovations. The mRNA vaccine market, particularly related to LNP delivery systems, has seen explosive growth and intense legal scrutiny.

Regulatory Implications

Arbutus operates within a highly regulated environment. Success hinges on navigating complex FDA (or equivalent) approval processes for its drug candidates. Furthermore, the outcomes of its ongoing patent litigations could have significant regulatory and commercial implications, potentially impacting market exclusivity and licensing opportunities.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-09-30: Nine Months Ended — Reported a significant reduction in net loss to $29.7M from $57.4M and a substantial increase in total revenue to $13.0M from $4.6M.
• 2025-09-30: Favorable Claim Construction Ruling — Received a favorable ruling in the intellectual property case against Pfizer/BioNTech, strengthening the company's legal position.
• 2025-12-31: Projected Cash Runway End — Company believes it has sufficient cash resources to fund operations for at least the next 12 months from the reporting date.
• 2026-03-01: Moderna LNP Litigation Trial — Scheduled trial date for the intellectual property dispute with Moderna, a critical event for potential future revenue streams.

Glossary

LNP Technology

Lipid Nanoparticle technology, used for delivering genetic material like mRNA into cells. Arbutus is involved in litigation regarding patents related to this technology. (Central to Arbutus's intellectual property disputes with major pharmaceutical companies.)

Deficit

Represents the accumulated losses of the company since its inception, reducing total stockholders' equity. (Indicates the company has historically operated at a net loss, common for early-stage biopharmaceutical firms.)

Contingent Consideration

An obligation to transfer additional assets or settle a liability in the future, depending on the outcome of certain future events. In this context, it may relate to past acquisitions or licensing deals. (Represents a potential future liability that can fluctuate based on performance or other triggers.)

Marketable Securities

Short-term, highly liquid investments that can be readily converted into cash. These are held by the company to generate returns and provide liquidity. (Part of Arbutus's cash position, contributing to its ability to fund operations.)

Year-Over-Year Comparison

Arbutus Biopharma has demonstrated significant operational improvements compared to the prior year's comparable period. Total revenue for the nine months ended September 30, 2025, more than doubled to $13.0 million from $4.6 million, primarily driven by collaborations and licenses. Operating expenses were substantially reduced by 31.5% to $45.9 million, largely due to decreased R&D spending. Consequently, the net loss narrowed considerably to $29.7 million from $57.4 million, representing a 48.2% improvement. The company's cash reserves have decreased, reflecting ongoing operational funding needs.

Filing Documents

• abus-20250930.htm (10-Q) — 963KB
• a2025-q310xqex311.htm (EX-31.1) — 10KB
• a2025-q310xqex312.htm (EX-31.2) — 10KB
• a2025-q310xqex321.htm (EX-32.1) — 5KB
• a2025-q310xqex322.htm (EX-32.2) — 5KB
• abus-20250930_g1.jpg (GRAPHIC) — 56KB
• 0001447028-25-000126.txt ( ) — 5502KB
• abus-20250930.xsd (EX-101.SCH) — 40KB
• abus-20250930_cal.xml (EX-101.CAL) — 43KB
• abus-20250930_def.xml (EX-101.DEF) — 201KB
• abus-20250930_lab.xml (EX-101.LAB) — 511KB
• abus-20250930_pre.xml (EX-101.PRE) — 359KB
• abus-20250930_htm.xml (XML) — 646KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1 ITEM 1.

FINANCIAL STATEMENTS (UNAUDITED)

FINANCIAL STATEMENTS (UNAUDITED) 1 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 36

OTHER INFORMATION

PART II. OTHER INFORMATION 37 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 37 ITEM 1A.

RISK FACTORS

RISK FACTORS 39 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 39 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 39 ITEM 4. MINE SAFETY DISCLOSURES 39 ITEM 5. OTHER INFORMATION 39 ITEM 6. EXHIBITS 40

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Balance Sheets (Unaudited) (In thousands of U.S. Dollars, except share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 22,408 $ 36,330 Investments in marketable securities, current 71,294 86,293 Accounts receivable 905 2,409 Prepaid expenses and other current assets 2,835 2,284 Total current assets 97,442 127,316 Property and equipment, net of accumulated depreciation and impairment of $ 13,347 (December 31, 2024: $ 12,996 ) 137 3,309 Right of use asset — 1,048 Other non-current assets 131 34 Total assets $ 97,710 $ 131,707 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued liabilities $ 4,653 $ 7,564 Deferred license revenue, current — 7,571 Lease liability, current 531 483 Total current liabilities 5,184 15,618 Liability related to sale of future royalties 3,684 4,829 Deferred license revenue, non-current — 2,863 Contingent consideration 11,052 10,225 Lease liability, non-current 391 806 Total liabilities 20,311 34,341 Stockholders' equity Common shares Authorized: unlimited number without par value Issued and outstanding: 191,953,665 (December 31, 2024: 189,963,492 ) 1,418,560 1,410,025 Additional paid-in capital 83,285 82,048 Deficit ( 1,376,317 ) ( 1,346,572 ) Accumulated other comprehensive loss ( 48,129 ) ( 48,135 ) Total stockholders' equity 77,399 97,366 Total liabilities and stockholders' equity $ 97,710 $ 131,707 See accompanying notes to the condensed consolidated financial statements. 1 ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands of U.S. Dollars, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue Collaborations and licenses $ 280 $ 767 $ 11,809 $ 2,861 Non-cash ro